NCT06835361 - Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis | Biotech Hunter

Enrollment

264

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions

Candidal Vulvovaginitis (ICD-10 Code: B37.3)Vulvovaginal Candidiasis (VVC)

Interventions

DRUG

Clotrimazole+Lactulose.

Vaginal suppositories containing clotrimazole (100 mg) and lactulose (300 mg)

DRUG

Canesten (Clotrimazole)

Vaginal tablets containing clotrimazole (100 mg)

DRUG

Lactulose

Vaginal suppositories containing lactulose (300 mg)

Trial Locations (7)

RECRUITING

"Healthcare Institution 1st Central District Polyclinic of the Central District of Minsk", Minsk

RECRUITING

"Healthcare Institution 14th Central District Polyclinic of the Partizansky District of Minsk", Minsk

RECRUITING

"Healthcare Institution 2nd Central District Polyclinic of the Frunzensky District of Minsk", Minsk

RECRUITING

"Healthcare Institution 4th City Polyclinic of Minsk", Minsk

RECRUITING

"Healthcare Institution 5th City Clinical Polyclinic of Minsk", Minsk

RECRUITING

"State Institution Republican Center of Medical Rehabilitation and Balneotherapy", Minsk

RECRUITING

"SBI RR Regional Clinical Skin and Venereal Dispensary", Ryazan